The controversial CEO behind the 5,000% hike in the price of a drug often used by AIDS patients says he regrets the increase in price, but only because he didn’t raise the cost of the drug more.
“I probably would have raised the price higher,” Martin Shkreli, founder of Turing Pharmaceuticals said in response to a question about what he would have done differently if he could relive the past couple of months. “I think health care prices are inelastic. I could have raised it higher and made more profits for our shareholders.”
Shkreli spoke at Forbes’ Healthcare Summit on Thursday, where he said his responsibility was making more money for shareholders, despite criticism that his massive price hike would impact vulnerable patients. The CEO raised the price of the drug Daraprim from $13.50 per pill to $750 per pill earlier this year, leading to much criticism. He has defended his actions by insisting that very few people actually took the drug, which treats toxoplasmosis, that the price hike was justified.
“My shareholders expect me to make the most profit,” Shkreli said. “That’s the ugly, dirty truth.”
[Forbes]
More Must-Reads From TIME
- Jane Fonda Champions Climate Action for Every Generation
- Biden’s Campaign Is In Trouble. Will the Turnaround Plan Work?
- Why We're Spending So Much Money Now
- The Financial Influencers Women Actually Want to Listen To
- Breaker Sunny Choi Is Heading to Paris
- Why TV Can’t Stop Making Silly Shows About Lady Journalists
- The Case for Wearing Shoes in the House
- Want Weekly Recs on What to Watch, Read, and More? Sign Up for Worth Your Time
Contact us at letters@time.com